Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 37,809 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

37,809 Papers indexed
963 Papers AI scored
37,809 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

37809 results
B
AI -
Base 74.2
Rank 74.2
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.2/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 26.0; sample size: 60.0; recency: 80.0; abstract quality: 100.0.

B
AI -
Base 74.18
Rank 74.18
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.2/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 88.4; sample size: 40.0; recency: 90.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.2/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 50.8; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Base 74.16
Rank 74.16
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.2/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 50.8; sample size: 60.0; recency: 90.0; abstract quality: 100.0.

B
Patients with uHCC and Child-Pugh B8/9 also benefit from a combination of antiangiogenic agents and PD-1 inhibitors: a multicenter real-world study.
PMID 40325791 Published: 2025-05-05 Ingested: 2026-08-02 12:04 AM Acta oncologica (Stockholm, Sweden)
AI -
Base 74.16
Rank 74.16
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.2/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 50.8; sample size: 60.0; recency: 90.0; abstract quality: 100.0.

B
The Clinical outcomes following pencil beam scanning proton therapy for skull base chordoma and chondrosarcoma: a single-institution experience.
PMID 42535416 Published: 2026-07-31 Ingested: 2026-08-02 09:15 AM Acta oncologica (Stockholm, Sweden)
AI -
Base 74.14
Rank 74.14
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 78.2; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

B
Temporal dynamics of substance P and its association with cytokine release syndrome after CD19 CAR-T therapy in pediatric B-ALL.
PMID 42265809 Published: 2026-06-10 Ingested: 2026-08-02 12:07 AM Stem cell research & therapy
AI -
Base 74.14
Rank 74.14
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 93.2; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Base 74.14
Rank 74.14
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 78.2; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.1/100. Study design: 75.0; human relevance: 90.0; therapeutic relevance: 38.2; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Base 74.14
Rank 74.14
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.1/100. Study design: 80.0; human relevance: 95.0; therapeutic relevance: 45.7; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

Previous
Page 377 of 3151
Next
Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic